Bone marrow aspirate, 2 months prior to CART-19 infusion, Wright-Giemsa, 10x: Wright-Giemsa stain of the bone marrow aspirate obtained two months prior to CART-19 therapy demonstrates rare megakaryocytes, numerous mononuclear cells, and virtually no maturing myeloid series. Bone marrow aspirate, 2 months prior to CART-19 infusion, Wright-Giemsa, 10x: Wright-Giemsa stain of the bone marrow aspirate obtained two months prior to CART-19 therapy demonstrates rare megakaryocytes, numerous mononuclear cells, and virtually no maturing myeloid series.
Bone marrow aspirate, 2 months prior to CART-19 infusion, Wright-Giemsa, 50x: Numerous blasts accounting for 87% of total cellularity and rare maturing erythroid precursors are identified.Bone marrow aspirate, 2 months prior to CART-19 infusion, Wright-Giemsa, 50x: Numerous blasts accounting for 87% of total cellularity and rare maturing erythroid precursors are identified.
Bone marrow aspirate, 2 months prior to CART-19 infusion, Wright-Giemsa, 100x: Medium-sized blasts have large round nuclei, fine chromatin, variably prominent nucleoli, and scant deep blue cytoplasm. A rare band-form neutrophil is seen in this field.Bone marrow aspirate, 2 months prior to CART-19 infusion, Wright-Giemsa, 100x: Medium-sized blasts have large round nuclei, fine chromatin, variably prominent nucleoli, and scant deep blue cytoplasm. A rare band-form neutrophil is seen in this field.
Bone marrow aspirate, 2 months prior to CART-19 infusion, flow cytometry: Flow cytometry performed on this bone marrow aspirate shows a distinct population of cells with CD45 vs. side scatter characteristics of blasts that represents 84% of total events. These blasts have the following immunophenotype: HLA-DR+, CD9+, CD19+, CD10+, CD20-, CD34(subset), CD38+, cCD79a+, CD24+, and TdT+.Bone marrow aspirate, 2 months prior to CART-19 infusion, flow cytometry: Flow cytometry performed on this bone marrow aspirate shows a distinct population of cells with CD45 vs. side scatter characteristics of blasts that represents 84% of total events. These blasts have the following immunophenotype: HLA-DR+, CD9+, CD19+, CD10+, CD20-, CD34(subset), CD38+, cCD79a+, CD24+, and TdT+.
Bone marrow aspirate, 2 months prior to CART-19 infusion, cytogenetics: Conventional cytogenetics performed on this bone marrow aspirate shows an abnormal karyotype of 48,XX,del(9)(p21.3),+11,del(14)(q2?q24),+16/46,XX[4].Bone marrow aspirate, 2 months prior to CART-19 infusion, cytogenetics: Conventional cytogenetics performed on this bone marrow aspirate shows an abnormal karyotype of 48,XX,del(9)(p21.3),+11,del(14)(q2?q24),+16/46,XX[4].
Bone marrow aspirate (Case S-12-005152), 3 months post CART-19 infusion, Wright-Giemsa, 10x: Three months post-treatment, the aspirate smear shows a mildly hypocellular marrow with trilineage hematopoiesis. Bone marrow aspirate (Case S-12-005152), 3 months post CART-19 infusion, Wright-Giemsa, 10x: Three months post-treatment, the aspirate smear shows a mildly hypocellular marrow with trilineage hematopoiesis.
Bone marrow aspirate (Case S-12-005152), 3 months post CART-19 infusion, Wright-Giemsa, 50x: Myeloid series are left shifted.Bone marrow aspirate (Case S-12-005152), 3 months post CART-19 infusion, Wright-Giemsa, 50x: Myeloid series are left shifted.
Bone marrow aspirate (Case S-12-005152), 3 months post CART-19 infusion, Wright-Giemsa, 100x: No evidence of residual leukemia is identified.Bone marrow aspirate (Case S-12-005152), 3 months post CART-19 infusion, Wright-Giemsa, 100x: No evidence of residual leukemia is identified.
Bone marrow core biopsy (Case S-12-005152), 3 months post CART-19 infusion, H&E, 20x: The bone marrow core biopsy obtained at the same time confirms a mildly hypocellular marrow with trilineage hematopoiesis, and no evidence of residual leukemia.Bone marrow core biopsy (Case S-12-005152), 3 months post CART-19 infusion, H&E, 20x: The bone marrow core biopsy obtained at the same time confirms a mildly hypocellular marrow with trilineage hematopoiesis, and no evidence of residual leukemia.
Bone marrow aspirate, 3 months post CART-19 infusion, flow cytometry: Flow cytometry shows immunophenotypically normal T cells and virtually no B cells.Bone marrow aspirate, 3 months post CART-19 infusion, flow cytometry: Flow cytometry shows immunophenotypically normal T cells and virtually no B cells.
Bone marrow aspirate, 3 months post CART-19 infusion, flow cytometry: Gating for potential blasts shows no residual leukemia.Bone marrow aspirate, 3 months post CART-19 infusion, flow cytometry: Gating for potential blasts shows no residual leukemia.
Bone marrow core biopsy (Case S-12-007268), 6 months post CART-19 infusion, H&E, 20x: Bone marrow biopsy obtained six months post CART-19 shows a normocellular marrow with trilineage hematopoiesis, and no evidence of leukemia.Bone marrow core biopsy (Case S-12-007268), 6 months post CART-19 infusion, H&E, 20x: Bone marrow biopsy obtained six months post CART-19 shows a normocellular marrow with trilineage hematopoiesis, and no evidence of leukemia.